Biotechnology, Healthcare, and Research by Gilead Sciences
Gilead Sciences stock continues downward trend amid oversold signals and resistance at 132.29
Gilead Sciences is sharing personal stories from hepatitis B carriers in Asian-Pacific nations to raise awareness about the link between HBV and liver cancer.Participants reflect on what they wish ...
Gilead Sciences stock trades down at $128.10 after positive HIV trial update, Gilead Sciences reports
Gilead Sciences announced positive topline results from a Phase 3 study of an investigational long-acting oral HIV treatment in collaboration with Merck.The announcement was made today. Gilead ...
Gilead Sciences stock trades up with weak intraday momentum amid HIV partnership expansion
Gilead Sciences said access to long-acting HIV prevention medication is accelerating because of the leadership of the South African government and the Global Fund.The company said this effort ...
Gilead Sciences stock drops 2.59% as collaboration with WHO on kala-azar elimination renewed, Gilead Sciences
Gilead Sciences held a high-level meeting with the WHO on the sidelines of the 79th World Health Assembly to announce the five-year renewal of their collaboration to accelerate progress toward ...
Focus on HIV therapies propels Gilead Sciences stock consolidation amid mixed technical momentum
Gilead Sciences says the needs of people living with HIV drive its research teams. The company is focusing on putting people at the center of developing new therapies.Gilead Sciences states it is ...
Gilead Sciences stock consolidates as executive spotlights new HIV prevention development approach
Gilead Sciences said Stacey Ma explained how nearly two decades of high-stakes problem-solving, cutting edge science and cross-functional teamwork paved the way for a new approach to HIV ...
Gilead Sciences to acquire Ouro Medicines in push for autoimmune disease therapies
Gilead Sciences has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases. ...
Gilead Sciences initiates challenging study for aggressive breast cancer form
Gilead Sciences is advancing its research into metastatic triple negative breast cancer (mTNBC), one of the most aggressive forms of the disease, by launching a more challenging crossover clinical ...
Gilead Sciences ASCENT-04 regimen gains Category 1 status in updated NCCN guidelines
Gilead Sciences announced that its Phase 3 ASCENT-04 trial results have now been incorporated into the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a ...
HIV prevention efforts amplified through music at SXSW, Gilead Sciences asserts
Gilead Sciences takes a leading role at this year SXSW in Austin, joining crucial conversations shaping the future of healthcare. The company is focusing its efforts on amplifying HIV prevention ...
Gilead Sciences stock forecast for 2030: Can $7.8B Arcellx deal push GILD to $220 with no patent cliff until 2036?
Gilead agreed to acquire Arcellx for $7.8 billion on February 23 to take full control of anito-cel, a next-generation CAR T-cell therapy for multiple myeloma with an FDA decision date of ...
Gilead Sciences pledges over $3 million to bolster US food security efforts
Gilead Sciences has announced a significant financial contribution through the Gilead Foundation, pledging over $3 million in grants. These funds are aimed at expanding access to food in ...
Gilead Sciences expands US workforce to 10,500
Gilead Sciences has announced the expansion of its US team to 10,500 members, signaling its commitment to growth and innovation. Behind each numerical gain, Gilead highlights the personal ...
Gilead Sciences accelerates efforts towards ending HIV epidemic at EACS2025
Gilead Sciences announced its plans to participate in the EACS 2025, underlining a commitment to the HIV community. The company aims to share insights on long-term treatment outcomes, expand ...
